APLIF - Mid-stage study of Appili Therapeutics' favipiravir in COVID-19 underway

The first participants have been dosed in a Phase 2 clinical trial evaluating Appili Therapeutics' (APLIF) favipiravir as a preventative measure against COVID-19 outbreaks in long-term care ((LTC)) facilities.The trial will include elderly subjects with comorbidities at 16 LTC centers and front-line healthcare workers with recent COVID-19 exposure or confirmed infection.The primary endpoint is the control of the outbreak, defined as no new microbiologically confirmed cases of COVID-19 for at least 24 consecutive days.Favipiravir is an orally administered broad-spectrum antiviral developed by FUJIFILM Toyama Chemical. It is sold in Japan under the brand name Avigan for the treatment of influenza and as a stockpile countermeasure against pandemic influenza.Topline data should be available in 2021.

For further details see:

Mid-stage study of Appili Therapeutics' favipiravir in COVID-19 underway